163 results on '"Gorla, Roberto"'
Search Results
2. Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic
3. Incidence du cancer chez les patients atteints de spondyloarthrite traités par anti-TNF
4. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry.
5. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs
6. Polyarthrite rhumatoïde : réponse clinique précoce sous certolizumab prédictive d’une faible activité de la maladie à un an en situation de “vraie vie”. Évaluation du registre italien GISEA
7. Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs
8. Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based study
9. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry
10. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register
11. Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores
12. Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modérés ou élevés
13. Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry
14. Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
15. The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod
16. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register
17. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study
18. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study
19. Fibromyalgia position paper
20. Diagnostic and therapeutic care pathway for fibromyalgia
21. Detection of Clonal T Cell Populations with Closely Related T Cell Receptor Junctional Sequences in Persons at High Risk for Human Immunodeficiency Virus (HIV) Infection and in Patients Acutely Infected with HIV
22. Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study
23. Impact of one-year treatment with biotechnological drugs on work ability in patients with rheumatoid arthritis in Italy: a prospective real-life study
24. Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic
25. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study
26. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
27. P74 Complement variations in systemic lupus erythematosus pregnancies
28. TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
29. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA
30. Thromboembolic events after fetal loss in patients with antiphospholipid syndrome: Comment on the article by Erkan et al
31. HYDROXYCHLOROQUINE IN PREGNANT PATIENTS WITH RHEUMATIC DISEASE: GESTATIONAL AND NEONATAL OUTCOME.
32. THU0519 DISEASE COURSE AND OUTCOMES OF PREGNANCY IN JUVENIL IDIOPHATIC ARTHRITIS: ANY DIFFERENCE AMONG DISEASE SUBSETS?
33. SAT0127 LONG-TERM OUTCOME OF CHILDREN BORN TO MOTHERS WITH CHRONIC ARTHRITIS AND EXPOSED TO TNF-INHIBITORS DURING PREGNANCY: A CASE-CONTROL STUDY
34. SAT0129 DISEASE FLARES DURING PREGNANCY IN RHEUMATOID ARTHRITIS: WHAT IS THE IMPACT OF STOPPING BDMARDS AT THE BEGINNING OF PREGNANCY?
35. FRI0387 DISEASE COURSE AND OUTCOMES DURING PREGNANCY IN PATIENTS WITH AXIAL SPONDILOARTHRITIS: COMPARISON BETWEEN TNFI USERS AND NAIVE PATIENTS
36. AB0446 REAL-LIFE USE OF BARICITINIB IN RHEUMATOID ARTHRITIS: A MULTICENTER OBSERVATIONAL STUDY OF 150 PATIENTS
37. FRI0042 CERTOLIZUMAB PEGOL EFFECTIVENESS IN WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE ANALYSIS OF AN INTERNATIONAL MULTICENTRE COHORT
38. Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry
39. Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
40. Budget impact analysis of the etanercept biosimilar: the Italian scenario
41. Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA
42. Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
43. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry
44. Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years
45. Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors
46. Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry
47. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry
48. Switching rheumatoid arthritis treatments: An update
49. Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry
50. Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.